Berlex Signs License Agreement with GeneGo
News Mar 16, 2006
The license provides researchers at Berlex and its German parent company with use of the MetaCore platform for analysis of gene expression, proteomic, metabolic and other high-throughput data in multiple therapeutic areas, including oncology, and in diagnostic applications.
"We are very pleased to bring MetaCore into our research," said Hugh Salamon, senior computational biologist, Berlex.
"It is essential to exploit curation of scientific findings given the large body of knowledge relevant to therapeutic research. GeneGo is providing us with an important view of current knowledge of mammalian signaling, metabolism, drugs and diseases through the MetaCore platform."
"We are very pleased that researchers at Berlex Biosciences, the US research center for Berlex, will be using MetaCore and to have the company as a GeneGo customer," said Julie Bryant, Vice President of Business Development at GeneGo.
"Berlex researchers will be among more than 140 unique accounts and thousands of users. Feedback from such partnerships help us enhance MetaCore as a versatile, multi-purpose data mining tool applicable in diverse life science projects."
3-D Printed Sugar Scaffolds Offer Sweet Solution for Tissue EngineeringNews
University of Illinois engineers built a 3-D printer that offers a sweet solution to making detailed structures that commercial 3-D printers can’t: Rather than a layer-upon-layer solid shell, it produces a delicate network of thin ribbons of hardened isomalt, the type of sugar alcohol used to make throat lozenges.READ MORE
Schizophrenics' Blood Contains RNA From More MicrobesNews
The blood of schizophrenia patients features genetic material from more types of microorganisms than that of people without the debilitating mental illness, research at Oregon State University has found. What’s not known is whether that’s a cause or effect of the severe, chronic condition that strikes about one person in 100.READ MORE